4,4,4-三氟-2,2-二甲基丁酸 | 939399-07-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4,4,4-三氟-2,2-二甲基丁酸
• 英文名称: 4,4,4-trifluoro-2,2-dimethylbutanoic acid
• CAS: 939399-07-2
• 化学式: C₆H₉F₃O₂
• 分子量: 170.131
• InChiKey: GCPLLNZGWOPZLF-UHFFFAOYSA-N

物化性质

• 沸点：
  175.6±35.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,4,4-三氟-2,2-二甲基丁酸 在 lithium aluminium tetrahydride 、 氨 、 N,N'-羰基二咪唑 作用下， 以 乙醚 为溶剂， 反应 30.5h， 生成 4,4,4-三氟-2,2-二甲基丁烷-1-胺
  参考文献：
  名称：

  Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-Indolecarboxamides: Identification of 4-[[5-[((2R)-2-Methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a Potent, Orally Active Antagonist of Leukotrienes D4 and E4

  摘要：

  The continued exploration of a series of 3-(arylmethyl)-1H-indole-5-carboxamides by the introduction of fluorinated amide substituents has resulted in the discovery of 4-[[5-[((2R)-2-methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide (38p, ZENECA ZD 3523),which has been chosen for clinical evaluation. This compound exhibited a K-i of 0.42 nM for displacement of [H-3]LTD(4) on guinea pig lung membranes, a pK(B) Of 10.13 +/- 0.14 versus LTE(4) on guinea pig trachea, and an oral ED(50) Of 1.14 mu mol/kg opposite LTD(4)-induced bronchoconstriction in guinea pigs. The R enantiomer was found to be modestly more potent than the S enantiomer 38o. Modification of the amide substituent to afford achiral compounds was unsuccessful in achieving comparable levels of activity. Profiling of 38p opposite a variety of functional assays has demonstrated the selectivity of this compound as a leukotriene receptor antagonist. The enantioselective synthesis of 38p, which employed a diastereoselective alkylation of (4R,5S)-3-(1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazolidinone (27) as the key step to establish the chirality of the amide substituent, provided an efficient route for generating 38p in >99% enantiomeric purity.

  DOI：

  10.1021/jm00035a008
• 作为产物：
  描述：

  乙基4,4,4-三氟-2-甲基丁酸酯 在 lithium hydroxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 4,4,4-三氟-2,2-二甲基丁酸
  参考文献：
  名称：

  Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-Indolecarboxamides: Identification of 4-[[5-[((2R)-2-Methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a Potent, Orally Active Antagonist of Leukotrienes D4 and E4

  摘要：

  The continued exploration of a series of 3-(arylmethyl)-1H-indole-5-carboxamides by the introduction of fluorinated amide substituents has resulted in the discovery of 4-[[5-[((2R)-2-methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide (38p, ZENECA ZD 3523),which has been chosen for clinical evaluation. This compound exhibited a K-i of 0.42 nM for displacement of [H-3]LTD(4) on guinea pig lung membranes, a pK(B) Of 10.13 +/- 0.14 versus LTE(4) on guinea pig trachea, and an oral ED(50) Of 1.14 mu mol/kg opposite LTD(4)-induced bronchoconstriction in guinea pigs. The R enantiomer was found to be modestly more potent than the S enantiomer 38o. Modification of the amide substituent to afford achiral compounds was unsuccessful in achieving comparable levels of activity. Profiling of 38p opposite a variety of functional assays has demonstrated the selectivity of this compound as a leukotriene receptor antagonist. The enantioselective synthesis of 38p, which employed a diastereoselective alkylation of (4R,5S)-3-(1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazolidinone (27) as the key step to establish the chirality of the amide substituent, provided an efficient route for generating 38p in >99% enantiomeric purity.

  DOI：

  10.1021/jm00035a008

文献信息

• 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
  申请人：Lange H.M. Josephus

  公开号：US20070142362A1

  公开（公告）日：2007-06-21

  This invention is directed to 4,5-dihydro-(1H)-pyrazole(pyrazoline) derivatives as cannabinoid CB 1 receptor modulators, to pharmaceutical compositions containing these compounds, to methods for the preparation of these compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which CB 1 receptors are involved, or that can be treated via manipulation of those receptors. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

  这项发明涉及作为大麻素CB1受体调节剂的4,5-二氢-(1H)-吡唑烯(吡唑啉)衍生物，含有这些化合物的药物组合物，制备这些化合物的方法，用于制备其合成有用的新中间体的方法，以及制备组合物的方法。该发明还涉及这些化合物和组合物的用途，特别是它们在向患者施用以在涉及CB1受体的疾病中实现治疗效果，或者可以通过操纵这些受体来治疗的疾病中的用途。 这些化合物具有通式(I) 其中符号的含义如规范中所述。
• [EN] HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS<br/>[FR] COMPOSÉS SPIRO HÉTÉROCYCLIQUES CONSTITUANT DES INHIBITEURS DU RÉCEPTEUR DE L'AM2
  申请人：UNIV SHEFFIELD

  公开号：WO2020099882A1

  公开（公告）日：2020-05-22

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

  揭示了式(I)的化合物及其药学上可接受的盐：其中HET、R1、R2、R3、R4、R5、L、L1、X1、X2、X3和q如本文所定义。这些化合物是肾上腺髓质素受体亚型2（AM2）的抑制剂。还揭示了这些化合物用于治疗调节AM2的疾病，包括增殖性疾病如癌症；包含这些化合物的药物组合物；制备这些化合物的方法；以及制备这些化合物的有用中间体。
• HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：US20170057943A1

  公开（公告）日：2017-03-02

  The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer including colorectal cancer. The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.

  本发明提供了一种具有mPGES-1抑制活性的化合物，用于预防或治疗疼痛、风湿病、骨关节炎、发热、阿尔茨海默病、多发性硬化症、动脉硬化、青光眼、眼压增高、缺血性视网膜疾病、全身性硬皮病和/或包括结直肠癌在内的癌症。本发明涉及具有化学式[I-a]、[I-b]或[I-c]的化合物或其药学上可接受的盐：其中每个符号如规范中所定义。
• Palladium(0)/PAr₃-Catalyzed Intermolecular Amination of C(sp³)H Bonds: Synthesis of β-Amino Acids
  作者：Jian He、Toshihiko Shigenari、Jin-Quan Yu

  DOI：10.1002/anie.201502075

  日期：2015.5.26

  An intermolecular C(sp3)H amination using a Pd0/PAr3 catalyst was developed. The reaction begins with oxidative addition of R2NOBz to a Pd0/PAr3 catalyst and subsequent cleavage of a C(sp3)H bond by the generated PdNR2 intermediate. The catalytic cycle proceeds without the need for external oxidants in a similar manner to the extensively studied palladium(0)‐catalyzed CH arylation reactions. The

  分子间C（SP 3） ħ胺化使用Pd 0 / PAR 3催化剂的开发。反应开始与氧化加成的R 2 Ñ  OBZ给PD 0 / PAR 3催化剂和C的随后裂解（SP 3） H键由所生成的Pd  NR 2中间。与广泛研究的钯（0）催化的CH芳基化反应相似，无需外部氧化剂即可进行催化循环。缺电子的三芳基膦配体对此C（sp 3）至关重要发生氨化反应。
• Nickel-Catalyzed Aminoxylation of Inert Aliphatic C(sp³)–H Bonds with Stable Nitroxyl Radicals under Air: One-Pot Route to α-Formyl Acid Derivatives
  作者：Chunxia Wang、Luoqiang Zhang、Jingsong You

  DOI：10.1021/acs.orglett.7b00479

  日期：2017.4.7

  Nickel-catalyzed aminoxylation of an unactivated C(sp3)–H bond with a stable nitroxyl radical has been accomplished for the first time to offer various N-alkoxyamine derivatives, which further enables a one-pot approach to α-formyl acid derivatives. The aminoxylation process reported also provides direct evidence for the oxidative addition of a cyclometallic intermediate with a free radical, which

  镍催化未活化的C（sp 3）-H键与稳定的硝酰基自由基的氨氧化反应已首次完成，以提供各种N-烷氧基胺衍生物，这进一步使一锅法制备α-甲酰基酸衍生物成为可能。报道的氨氧化过程也为环金属中间体与自由基的氧化加成提供了直接证据，这对过渡金属催化的惰性C（sp 3）-H键的官能化反应机理的研究很有帮助。